Results From the Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion-Dependent Non-del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents
07:30am - 03:35pm EST - April 6, 2024
07:30am - 03:35pm EST - April 6, 2024
Abstract: JNCCN23-0640 https://jnccn.org/view/journal...
Author(s):
- Yazan Madanat, MD, UT Southwestern Simmons Comprehensive Cancer Center
Tags: Member Institution Clinical Oncology Top Abstract
| Display Label | Action |
|---|---|
| Madanat_NCCN2024_IMerge_Poster_FINAL_28Feb2024.pdf | Download Handout |
| AC24P103 - Results From the Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion-Dependent Non-del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to/Ineligible for Erythropoiesis Sti | Download MP3 |